SYBX SYNLOGIC, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1527599 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-99.8%
TTM net income YoY59.2%
TTM EPS YoY79.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-511,875.0%
Net margin-291,987.5%
FCF margin-395,900.0%
EBITDA margin-507,537.5%
Returns
ROE-102.6%
ROA-49.0%
ROIC (approx.)-2,394.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets35.7%
Debt / equity0.00x
Current ratio2.80x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.36x
Accruals ratio17.4%
Payout ratio—
Capex / revenue175.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | — | — | $49,000 | — | — | — | $22,000 | — |
| SG&A expense | $695,000 | $828,000 | $1.06M | $1.03M | $818,000 | $800,000 | $836,000 | $1.40M |
| Operating income | -$2.30M | -$1.01M | -$1.32M | -$1.34M | -$991,000 | -$777,000 | -$898,000 | -$1.78M |
| Interest expense | — | — | — | — | — | — | — | $0 |
| Pretax income | — | — | — | $1.51M | -$2.30M | -$529,000 | — | -$714,000 |
| Income tax | — | — | — | $0 | $0 | $0 | — | $0 |
| Net income | -$3.87M | -$543,000 | $681,000 | $1.51M | -$2.30M | -$529,000 | $317,000 | -$714,000 |
| EBITDA | — | — | — | -$1.34M | -$991,000 | -$777,000 | -$898,000 | -$1.78M |
| EPS (basic) | -0.31 | -0.04 | 0.05 | — | -0.19 | -0.04 | 0.03 | — |
| EPS (diluted) | -0.31 | -0.04 | 0.05 | — | -0.19 | -0.04 | 0.03 | — |
| Weighted avg. shares (diluted) | 12.42M | 12.42M | 12.40M | — | 12.32M | 12.32M | 12.39M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $11.56M | $13.18M | $14.11M | $14.67M | $15.59M | $17.03M | $17.27M | $18.86M |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Current assets | $11.80M | $13.43M | $14.56M | $15.40M | $16.50M | $17.32M | $17.92M | $19.78M |
| PP&E, net | — | — | — | — | — | — | — | $0 |
| Total assets | $11.85M | $13.48M | $14.61M | $15.45M | $16.55M | $17.37M | $17.97M | $19.83M |
| Current liabilities | $1.67M | $1.46M | $2.06M | $3.58M | $6.23M | $4.78M | $4.87M | $7.08M |
| Total liabilities | $1.67M | $1.46M | $2.06M | $3.58M | $6.23M | $4.78M | $4.87M | $7.08M |
| Shareholders' equity | $10.18M | $12.02M | $12.55M | $11.86M | $10.32M | $12.59M | $13.09M | $12.75M |
| Shares outstanding | 12.25M | 11.70M | 11.70M | 11.70M | 11.70M | 11.70M | 11.70M | 11.70M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.62M | -$922,000 | -$563,000 | -$923,000 | -$1.44M | -$399,000 | -$1.60M | -$568,000 |
| Capital expenditure | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | — | — | — | -$923,000 | -$1.44M | -$399,000 | -$1.60M | -$568,000 |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $155,000 | $12,000 | $30,000 |
| Financing cash flow | — | — | — | $0 | $0 | $0 | $0 | $9,000 |
| Depreciation & amortization | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Stock-based compensation | $5,000 | $6,000 | $10,000 | $30,000 | $33,000 | $29,000 | $25,000 | $348,000 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.